Search research articles
Contact Us
Filters
Showing results (51-60 of 150) with videos related to
Page
of 15
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
May 9, 2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Sara A Scott, Danielle L Roberts, Vikas A Gupta, et al.
Haematologica
|
September 4, 2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
Lorenzo Cani, Sara A Scott, Danielle Roberts, et al.
Cancer
|
May 20, 2026
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3
Ajay K Nooka, Christopher Strouse, Sarah M Larson, et al.
Blood Cancer Journal
|
September 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Nisha S Joseph, Jonathan L Kaufman, Vilas A Gupta, et al.
European Journal of Medicinal Chemistry
|
August 25, 2017
Development of GLUT4-selective antagonists for multiple myeloma therapy
Changyong Wei, Richa Bajpai, Horrick Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Nisha S Joseph, Jonathan L Kaufman, Madhav V Dhodapkar, et al.
Blood Cancer Journal
|
December 19, 2023
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Sara A Scott, Ellen M Marin, Kathryn T Maples, et al.
American Journal of Hematology
|
December 4, 2020
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience
Kathryn T Maples, Ajay K Nooka, Vikas Gupta, et al.
The Journal of Biological Chemistry
|
April 8, 2015
In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy
Rama K Mishra, Changyong Wei, Richard C Hresko, et al.
Transplantation and Cellular Therapy
|
October 9, 2021
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life
Nisha S Joseph, Vikas A Gupta, Sarah Wyman, et al.
Page
of 15
Search research articles
Search
Showing results (51-60 of 150) with videos related to
Sort By:
Page
of 15
Clinical Lymphoma, Myeloma & Leukemia
|
May 9, 2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Sara A Scott, Danielle L Roberts, Vikas A Gupta, et al.
Haematologica
|
September 4, 2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
Lorenzo Cani, Sara A Scott, Danielle Roberts, et al.
Cancer
|
May 20, 2026
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3
Ajay K Nooka, Christopher Strouse, Sarah M Larson, et al.
Blood Cancer Journal
|
September 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Nisha S Joseph, Jonathan L Kaufman, Vilas A Gupta, et al.
European Journal of Medicinal Chemistry
|
August 25, 2017
Development of GLUT4-selective antagonists for multiple myeloma therapy
Changyong Wei, Richa Bajpai, Horrick Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Nisha S Joseph, Jonathan L Kaufman, Madhav V Dhodapkar, et al.
Blood Cancer Journal
|
December 19, 2023
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Sara A Scott, Ellen M Marin, Kathryn T Maples, et al.
American Journal of Hematology
|
December 4, 2020
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience
Kathryn T Maples, Ajay K Nooka, Vikas Gupta, et al.
The Journal of Biological Chemistry
|
April 8, 2015
In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy
Rama K Mishra, Changyong Wei, Richard C Hresko, et al.
Transplantation and Cellular Therapy
|
October 9, 2021
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life
Nisha S Joseph, Vikas A Gupta, Sarah Wyman, et al.
Page
of 15